References

Abber JC, Lue TF, Luo J, Juenemann K & Tanagho EA (1987) Priapism induced by chlorpromazine and trazodone: Mechanism of action. J Urol 137: 1039-1042.

Abber JC, Lue TF, Orvis BR, McClure RD & Williams RD (1986) Diagnostic tests for impotence: A comparison of papaverine injection with penile-brachial index and nocturnal penile tumescence monitoring. J Urol 135: 923-925.

Aboseif SR, Baskin LS, Yen TS, Benedict Y & Lue TF (1992) Congenital defect in sinusoidal smooth muscles: A cause of organic impotence. J Urol 148: 58-60.

Aboseif SR, Breza J, Bosch RJLH, Benard F, Stief CG, Stackl W, Lue TF & Tanagho EA (1989) Local ans systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1 and saline in primates. J Urol 142: 403-408.

Abrams HS, Hester LR, Sheridan WF & Epstein GM (1975) Sexual functioning in patients with chronic renal failure. J Nerv Ment Dis 160: 220-226.

Andersen BL & Broffitt (1988) Is there a reliable and valid self-report measure of sexual behavior? Arch Sex Behav. 17: 509-525.

Andersson KE, Holmquist F & Wagner G (1991) Pharmacology of drugs used for treatment of erectile dysfunction and priapism. Int J Impot Res 3: 155-172.

Aoki H, Matsuzaka J, Yeh KH, Banya Y, Fuzioka T, Kubo T & Yasuda N (1990) Studies on the role of VIP (vasoactive intestinal polypeptide) in penile erectile dysfunction. Int J Impot Res 2(Suppl 2): 28-29.

Aravena EP & Bustamente E (1986) Treatment of psychogenic erectile incompetence with intracavernous injection of papaverine In: Proceedings of the fifth Conference on Vasoculogenic Impotence and Corpus Cavernosal Revascularisation. Second World Meeting on Impotence. Prague: International Society for Impotence Research (ISIR) 11: 18.

Aserinsky E & Kleitman N (1953) Regularly occuring periods of eye motility and concominant phenomena during sleep. Science 118: 273-274.

Azadzoi KM, Payton T, Krane RJ & Goldstein I (1990) Effects of intracavernosal trazodone hydrochloride: animal and human studies. J Urol 144: 1277-1282.

Bagatell CJ, Heiman JR, Rivier JE & Bremner WJ (1994) Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab: 711-716.

Baltaci S, Aydos K, Kosar A & Anafarta K (1995) Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol 74: 102-105.

Barnes P (1991) Role of sex therapy in the management of erectile dysfunction. In: Kirby RS, Carson C, Webster GD, eds. Impotence: diagnosis and management. Oxford, Butterworth-Heinemann: 133-142.

Becker AJ, Stief CG, Machtens S, Schultheiss D, Hartmann U, Truss MC & Jonas U (1998) Oral phentolamine as treatment for erectile dysfunction. J Urol 159 (4): 1214-1216

Benard F & Lue TF (1990) Self-Administration in the Pharmacological Treatment of Impotence. Drugs 39: 394-398.

Benet AE & Melman A (1995) The epidemiology of erectile dysfunction. Urol.Clin.NA 22(4): 701.

Bennet AH, Carpenter AJ & Barada JH (1991) An improved vasoactive drug combination for pharmacological erection program. J Urol 146: 1564-1565.

Bolt JW, Evans C & Marshall VR (1987) Sexual dysfunction after prostatectomy. Br J Urol 58: 319-322.

Bonithon-Kopp C, Scarabin PY, Bara L, Castanier M, Jacqueson A & Roger M (1988) Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 71: 71-76.

Boolell M, Allen MJ, Ballard SA et al (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47-52.

Bradley WE, Timm GW, Gallagher JM & Johnson BK (1985) New method for continuous measurement of nocturnal penile tumescence and rigidity. Urology 26: 4-9.

Braunstein GD (1983) Endocrine causes of impotence. Optimistic outlook for restoration of potency. Postgrad Med 74: 207-217.

Brecher EM (1984) Love, Sex and Aging. Boston: Little, Brown & Co.

Bremner WJ, Vitiello MV & Prinz PN (1983) Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 56: 1278-1281.

Brindley GS (1983a) Cavernosal alpha-blockade and human penile erection. J Physiol 342, 24P.

Brindley GS (1983b) Cavernosal alpha-blockage: a new technique for investigating and treating erectile impotence. Br J Psychiatry 143: 332-337.

Brindley GS (1986) Pilot experiments on the action of drugs injected into the human corpus cavernosum penis. Brit J Pharmacol 87: 495-500.

Brown J, Doxey JC & Handley S (1980) Effects of alfa-adrenoceptor agonists and antagonists and of antidepressant drugs on pre- and postsynaptic alfa-adrenoceptors. Eur J Pharmacol 67: 33-40.

Burnett AL (1995) The role of nitric oxide in the physiology of erection. Biol Reprod 52: 485-589.

Burnett AL (1997) Nitric oxid in the penis: physiology and pathology. J Urol 157: 320-324.

Burris AS , Banks SM, Carter CS, Davidson JM & Sherins RJ (1992) a long term, prospective study of physiologic and behavioral effects of hormone replacement in untreated hypogonadal men.J Androl 13: 297-304.

Bush PA, Aronson WJ, Buga GM, Rajfer J & Igrarro LJ (1992) Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 147: 1650-1655.

Buvat J, Buvat HM, Dehaene JL & Lemaire A (1986) Is intracavernous injection of papaverine a reliable screening test for vascular impotence? J Urol 135: 476-478.

Buvat J, Buvat-Herbaut M, Lemaire A & Marcolin G (1991) Reduced rate of fibrotic nodules in the cavernous bodies following auto-intracavernous injections of moxisylyte compared to papaverine. Int J Impot Res 3: 123-128.

Buvat J, Lemaire A, Buvat-Herbaut M & Marcolin G (1989) Safety of intracavernous injections using an alpha-blocking agent. J Urol 141: 1364-1367.

Buvat J, Lemaire A, Marcolin G, Dehaene JL & Buvat-Herbut M (1987) Intracavernous injection of papaverine (ICIP). Assessment of its diagnostic and therapeutic value in 100 impotent patients. World J Urol 5: 150-155.

Capetola RJ, Rosenthale ME, Dubinsky B & McGuire JL (1983) Peripheral antialgesics: a review. J Clin Pharmacol 23: 545-556.

Carroll JL, Ellis D & Bagley DH (1992) Impotence in the elderly: Evaluation of erectile failure in men older than seventy years of age. Jefferson Sexual Function Center. Urology 39: 226-230.

Cavallini G (1994) Minoxidil and capsacain: an association of transcutaneus active drugs for erection facilitation. Int J Impot Res 6 suppl. 1: D70.

Cavallini G (1991) Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneus erection facilitation for organic impotence. J Urol 146: 50-53.

Chao R & Clowers DE (1994) Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch Phys Med Rehabil 75: 276-278.

Chen J, Godschalk MF, Katz PG & Mulligan T (1995) Combining intracavernous injection and external vacuum devise as treatment for erectile dysfunction. J Urol 153: 1476-1477.

Chen RN, Lakin MM, Montaque DK & Ausmundson (1996) Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis. J Urol 155: 138-140.

Christ GJ, Brink PR, Brook S & Ney P (1996) PGE1-induced alterations in maxi-K+-channel activity in cultured human corporal smooth muscle cells. J Urol 155: 678A.

Claes H & Baert L (1989) Transcutaneus nitroglyserine therapy in the treatment of impotence. Int Urol 44: 309-312.

Clark JT, Smith ER & Davidson JM (1985) Testosterone is not required for the enhancement of sexual motiovation by yohimbine. Physiology and behavior 35: 517-521.

Cohen JC & Hickman R (1987) Insulin resistance and dimished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab (64): 960-963.

Condra M, Morales A, Surridge DH, Owen JA, Marshall P & Fenemore J (1986) The unreliability of nocturnal penile tumescence recording as an outcome measurement in the treatment of organic impotence. J Urol 135: 280-282.

Cookson MS & Nadig PW (1993) Long term results with vacuum constriction device. J Urol 149: 290-294.

Cooper AJ (1991) Evaluation of I-C papaverine patients with psychogenic and organic impotence. Can J Psychiatry 36: 574-577.

Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR & Williams RD (1998) Effect of exogenous testosterone on prostate volume, serum and semen prostate spesific antigen levels in healthy young men. J Urol 159(2): 441-443.

Costa P, Sarrazin B, Bressolle F, Colson MH, Bondil P & Saudurbray F (1993) Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. J Urol 149: 301-305.

Davis-Joseph B, Tiefer L & Melman A (1995) Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 45(3): 498-502.

de Lignieres B (1993) Transdermal dihydrotestosterone treatment of andropause. Ann Med 25: 235-241.

Deamer RL & Thompson JF (1991) The role of medications in geriatric sexual function Clin Geriatr Med 7: 95-111.

Dhabuwala CB, Ramakrishna VR & Anderson GF (1985) Beta-adrenergic receptors in human cavernous tissue. J Urol 133: 721-723.

Donatucci CF & Lue TF(1992) The combined intracavernous injection and stimulation test: Diagnostic accurancy. J Urol 148: 61-62.

Earle CM, Keogh EJ, Ker J, Cherry DJ, Glatthaar C, Tulloch AGS, Lord DJ & Wisniewski ZS (1990) Intracavernosal injection therapy for impotence due to spinal cord injury. Int J Impot Res: 2: 297-298.

Earle CM, Keogh EJ, Wisniewski ZS, Tulloch AgsS, Lord DJ, Watters GR & Glatthaar C (1990) Prostaglandin E1 therapy for impotence, comparison with papaverine. J Urol 143: 57-59.

Ehmke H, Junemann K-P, Mayer B & Kummer W (1995) Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the penile circulation. Int J Impotence Res 7: 147-156.

Ellis WJ & Grayhack JT (1963) Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 89: 895-899.

Ernst E & Pittler MH (1998) Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 159: 433-436.

Fahrenkrug J (1989)VIP and autonomic neurotransmission. Pharmacol Ther 41: 515-534.

Fallon B (1995) Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 22: 833-845.

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ & McKinlay JB (1994) Impotence and its medical and psychological correlates: Results of the Massachusetts male aging study. J Urol 151: 54-61.

Ferreira SH(1983) Prostaglandins: peripheral and central analgesia. In: Advances in Pain Research an Therapy. Edited by J.J. Bonica, U. Lindholm, A Iggo. New York, Raven Press, 5: 627-629.

Fiet J, Morville R, Chemama D, Villette JM, Gourmel B, Brerault JL & Dreux C (1982) Plasma androgen and gonadotrophin levels in normal adult men after percutaneus administration of 5-alfa-dihydrotestosterone. Int J Androl 5: 586-594.

Finkle AL & Prian DV (1966) Sexual potency in elderly men before and after prostatectomy. JAMA 196 (2): 139-143.

Fischer C (1965) Cycle of penile erection synchronous with dreaming sleep. Arch Gen Psychiatry 12: 29-45.

Flind AC (1984) Cavernosal alpha-blockade: a warning. Br J Psychiatr 144: 329-330.

Fouda A, Hassouna M, Beddoe E, Kalogeropoulos D, Binik YM & Elhiali MM (1989) Priapism: an avoidable complication of pharmacologically induced erection. J Urol 142: 995-997.

Frank E, Anderson C & Rubinstein D (1978) Frequency of sexual dysfunction in “normal“ couples. New Engl J Med 299: 111-115.

Fried LP, Moore RD & Person TA (1986) Long-term results of cigarette smoking and moderate alcohol consumption on coronary artery diameter. Mechanism of coronary artery disease independent of arteriosclerosis or thrombosis? Amer J Med 80: 37-44.

Friedman DE, Clare AW, Rees LH & Grossman A (1986) Should impotent males who have no clinical evidence of hypogonadism have routine endocrine screening? Lancet 1: 1041, Letter.

Gall H, Baehren W, Scherb W, Stief C & Thon W(1989) Diagnostic accuracy of Doppler ultrasound technique of the penile arteries in correlation to selective arteriography. Cardiovasc Intervent ­Radiol 11: 225-231.

Gerber GS & Levine LA (1991) Pharmacological erection program using prostaglandin E1. J Urol 146: 786-789.

Gillam DG, Bulman JS & Newman HN (1997) A pilot assessment of alternative methods of quantifying dental pain with particular reference to dentine hypersensitivity. Community Dent Health 14(2): 92-96.

Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD & Wicker PA (1998) oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397-1404.

Goldstein I & the Vasomax Study Group (1998) Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction J Urol 159: 240.

Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR & Kramer-Levien D (1993) Experience with triple-drug therapy in a pharmacological erection program. 150: 1822-1824.

Gray A, Feldman HA, McKinlay JB & Longcope C (1991) Age, disease, and changing sex hormone levels in middle-aged men: rsults of the Massachusetts male aging study. J Clin Endocrinol Metab 73: 1016-1025.

Grunhaus L, Tiogco D & Zelnik T (1989) Intravenous yohimbine: selective enhancer of norepinephrine and cortisol secretion and systolic blood pressure in humans. Clin Neuropharmacol 12: 106-111.

Gu J, Polak JM, Lazarides M, Pryor JP, Blank MA, Polak JM, Morgan R, Marangos PJ & Bloom SR (1984) Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet ii: 315-318.

Gwinup G (1988) Oral phentolamine in non-spesific erectile insufficiency. Ann Int Med 109: 162-163.

Hajjar RR, Kaiser FE & Morley JE (1997) Outcomes on long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab (82): 3793-3796.

Hakenberg O, Wetterauer U, Koppermann U & Luhman R (1990) Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impot Res 2: 247-248.

Halverson HM (1940) Genital and sphincter behavior of the male infant. J Gen Psychol 56: 95-99.

Handbury DC & Sethia KK (1995) Erectile function following transurethral prostatectomy. Br J Urol 75: 12-13.

Hargreave TB, Stephenson TP (1977) Potency and prostatectomy. Br J Urol 49: 683-688.

Hartmann U (1998) The efficacy of psychosexual therapy for erectile dysfunctions: a critical review of outcome studies and suggestions for future treatment strategies. J Impot Res 10: S23.

Hashmat AI, Abrahams J, Fani K & Nostrand I (1991) A lethal complication of papaverine-induced priapism. J Urol 145: 146-147.

Hatzichristou DG, Hatzhimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G & Kalinderis A (1998) Nocturnal penile tumescence and rigidity monitoring in young patient volunteers: reproducibility, evaluation criteria and the effect of sexual intercouse. J Urol 159(6): 1921-1926.

Heaton JPW, Morales A, Adams MA & Johnston B (1995) Recovery of erectile function by oral adminstration of apomorphine. Urology 45: 200-206.

Hedlund H & Andersson K-E (1985) Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 134: 1245-1250.

Holmäng S, Marin P, Lindstedt G & Hedelin H (1993) Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-spesific antigen concentration in eugonadal middle-aged men. Prostate 23: 99-106.

Holtgrewe HL, Valk WL (1964) Late results of transurethral prostatectomy. J Urol 92: 51-55.

Hwang T, Yang I-S, Wang C-R, Chang S-J, Tzai T-S, Chang C-H & Wu H-C (1989) Impotence evaluated by the use of prostaglandin E1. J Urol 141: 1357-1359.

Hwang TI, Yang C & Ho WL (1991) Histopathological changes of corpora cavernosa after long-term intracavernous injection. Eur Urol 20: 301-306.

Incrocci L, Hop WC & Slob AK (1996) Visual erotic and vibrotactile stimulation and intracavernous injection in screening men with erectile dysfunction: a 3 year experience with 406 cases. Int J Impot Res 8(4): 227-232.

Ischii N, Watanabe H, Irisawa C, Kikuchi Y, Kubota Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M & Shirai M (1989) Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 141: 323-325.

Ischii N, Watanabe H, Irisawa C & Kikuchi Y (1986) Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Zasshi 77: 954-962. (In Japanese.)

Janssen E, Everaerd W, Van Lunsen RH & Oerlemans S (1994) Visual stimulation facilitates penile responses to vibration in men with and without erectile dysorder. J Consult Clin Psychol 62: 1222-1228.

Johnson AR & Jarow JP (1992) Is routine endocrine testing of impotent men necessary? J Urol 147: 1542-1544.

Juenemann KP, Lue TF, Huo JA, Jadallah SI, Nunes LL & Tanagho EA (1987) The role of vasoactive intestinal polypeptide as a neuro-transmitter in a canine penile erection: a combined in vivo and immunohistochemical study. J Urol 138: 871-877.

Juneman KP & Alken P (1989) Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1: 71-93.

Karacan I (1970) Clinical value of nocturnal penile erection in the prognosis and diagnosis of impotence. Med Aspects Hum Sexual 4: 27, 31, 32, 34.

Karadenitz T, Topsakal M, Aydogmus A & Beksan M (1997) Role of Rigiscan in the etiologic differential diagnosis of erectile dysfunction. Urol Int 59(1): 41-45.

Katlowitz NM, Albano GJ, Morales P & Golimbu M (1993) Potentiation of drug-induced erection with audiovisual sexual stimulation. Urology 41(5): 431-434.

Kim ED, el Rashidy R & McVary KT (1995) Papaverine topical gel for treatment of erectile dysfunction. J Urol 153: 361-365.

Kim ED & McVary KT (1995) Long-term results with penile vein ligation for venogenic impotence. J Urol 153: 655-658.

Kim ED & McVary KT (1995) Topical prostaglandin-E1 for the treatment of erectile dysfunction. 153(6): 1828-1830.

Kim JH & Carson CC III (1993) Development of Peyronie`s disease with use of vacuum constriction device. J Urol 149: 1314-1355.

Kim SC, Lee SW & Seo KK (1997) Characteristics of pain following intracavernous injection of prostaglandin E1. J Korean Med 12(4): 327-331.

Kim SC & Oh MM (1992) Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence. J Urol 147: 1530-1532.

King J (1874) The american physician-domestic guide to health. Indianapolis: Streight and Douglass 384.

Kinsley AC, Pomeroy WB & Martin CE (1948) Sexual behavior in the human male. Philadelphia, WB Saunders, pp236-237.

Kirby RS (1994) Impotence: diagnosis and management of male erectile dysfunction. BMJ 308: 957-961.

Kirkeby H-J, Forman A & Andersson K-E (1990) Comparison of the papaverine effects on isolated human penile circuflex vein and corpus cavernosum. Int J Impot Res 2: 49-54.

Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Selver AJ, Viosca SP & Garza D (1990) Secondary hypogonadism in older men: its relation to impotence. J Clin Endocr Metab 71: 963-969.

Kosch SG, Curry RW, Jr & Kuritzky L (1988) Evaluation and treatment of impotence: a pragmatic approach addressing organic and psychogenic components. Fam. Prac Res J 7(3): 162-173.

Krane RJ, Goldstein I & Tejada S (1989) Impotence. N Engl J Med 321: 1648-1649.

Kuhn JM, Laudat MH, Lignieres B de, Bricaire H & Luton JP (1986) Traitement androgenique percutane des hypogonadismes masculins. Efficacite comparee de la testosterone et de la dihydrotestosterone: etude de 40 observations. Contrasept Fert Sex 14: 1031-1036.

Lakin MM, Montaque DK, Medendorp SV & Tesar L Schover LR (1989) Intracavernous injection therapy: analysis of results and complications J Urol 143: 1138-1141.

Lederer O (1913) Specification of letter patent. United States Patent Office # 1,225,341. Application filed Nov 29; serial No, 1917, 803,853 Granted May 8.

Lee LM, Stevenson RWD & Szasz G (1989) Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence. J Urol 141: 549-550.

Leonard M Nickel, JC & Morales A (1989) Hyperprolactinemia and impotence: why, when and how to investigate. J Urol 142: 992-995.

Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED & Resnick MI (1989) Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141: 54-57.

Lewis RW & Mayda J II (1994) Diagnosis and treatment of vasculogenic impotence. Acta Chir Hung 34: 231-241.

Libman E & Fichten CS (1987) Prostatectomy and sexual functions. Urology 29: 467-478.

Lilius HG, Valtonen EJ & Wikstrom J (1976) Sexual problems in patients suffering from multiple sclerosis. J Chron Dis 29: 643-647.

Linet OI & Ogrinc FG (1996) Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction.334: 873-877.

Lomas GM & Jarow JP (1994) Risk factors for papaverine-induced priapism. J Urol 147: 1280-1281.

Lue TF (1990) Impotence: a patient`s goal-directed approach to treatment. World J Urol 8: 67-74.

Lue TF(1990) Intracavernous Drug Administration: Its Role in Diagnosis and Treatment of Impotence.Seminars in Urology Vol VIII, No 2: 100-106.

Lue TF, Hricak H, Marich KW & Tanagho EA (1985) Vasculogenic impotence evaluated by high resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology 155: 777-781.

Lue TF & Tanagho EA (1987) Physiology of erection and pharmacological management of impotence. J Urol 137: 829-836.

Margolis R, Prieto P, Stein L & Chinn S (1971) Statiscical summary of 10.000 male cases using Afrodex in treatment of impotence. Curr Ther Res 13: 616-622.

Marin P, Hollmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G & Bjornthorp P (1992) The effects of testosterone treatment on body composition and metabolism in middle age obese men.Int J Obesity 16: 992-997.

Martins FE & Reis JP (1997) Visual erotic stimulation test for initial screening of psychogenic erectile dysfunction: a reliable nonoinvasive alternative? J Urol 157(1): 134-139.

McMahon CG (1991) A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin PGE1 and a combination of all three agents in the management of impotence. Int J Impot Res 3: 113-121.

McMahon CG (1996) A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. In J Impot Res 8: 233-236.

McMahon CG (1996) The return of spontaneus erections after self-injection of prostaglandin E1. Int J Impot Res 4: 179-186.

Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC & Writing Committee (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluationg 3885 patients. J Urol 141: 243-247.

Meinhardt W, Kropman RF, Lycklama a Nijeholt AAB & Zwartendjik J (1990) Skin necrosis caused by use of negative pressure device for erectile impotence. J Urol 144:983.

Meinhardt W, Schmitz PI, Kropman RF, de la Fuente RB, Lycklama a Nijeholt AA & Zwartendijk J (1997) Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res 9(3): 163-165.

Miller WW (1968) Afrodex in the treatment of impotence. A double-blind cross-over study. Curr Ther Res 10: 354-359.

Montorsi F, Guazzoni G, Barbieri L, Rigatti P, Pizzini G & Miani A (1996) The effect of intracorporeal injection plus genital and audiovisual sexual stimulation versus second injection on penile color Doppler sonography parameters. J Urol 155 (2): 536-540.

Montorsi F, Guazzoni G, Bergamaschi F, Dodedini A, Rigatti P, Pizzini G & Miani A (1993) Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence. Urology 42(5): 554-558.

Montorsi F, Strambi LF, Guazzoni G, Galli L, Barbieri L, Rigatti P, Pizini G & Miani A (1994) Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 44: 732-736.

Morales A, Heaton JP, Johnston B & Adams M (1995) Oral and topical treatment of erectile dysfunction: present and future. Urol Clin NA 22: 879-886.

Morales A, Johnston B, Heaton JP & Lundie M (1997) Testosterone supplementation for hypogonadal impotence:assessment of biochemical measures and therapeutic outcomes. J Urol 157: 849-854.

Morales A, Johnston B, Heaton JW & Clark A (1994) Oral androgens in the treatment of hypogonadal impotent men ( see comments). J Urol 152: 1115-1118.

Morales A, Surridge DH, Marshall PG & Fenemore J (1982) Nonhormonal pharmacological treatment of organic impotence. J Urol 128(1): 45-47.

Moriel EZ & Rajfer J (1993) Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol 149: 1299-1300.

Morley JE (1985) Impotence. Am J Med 80: 897-905.

Morley JE & Kaiser FE (1989) Sexual function with advancing age. Med Clin North Am 73: 1483-1495.

Morley JE, Perry M, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M & Perry HM (1993) Effects of testosterone replacement therapy in old hypogonadal males:a preliminary study. J Am Geriatr Soc 41: 149-152.

Mulligan T & Katz PG (1989) Why aged men become impotent. Arch Intern Med 149: 1365-1366.

Mulligan T, Retchin SM, Chinchilli VM & Bettinger CB (1988) The role of aging and chronic disease in sexual dysfunction. J Amer Geriat Soc 36: 520-524.

Murburg MM, Villacres EC, Ko GN & Veith RC (1991) Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrinol Metab 73: 861-865.

Nadig PW, Ware JC & Blumoff R (1986) Non invasive device to produce and maintain an erection-like state. Urology 27: 126-131.

Nahoul K & Roger M (1990) Age-related decline of plasma bioavailable testosterone in adult men. J Steroid Biochem 35: 293-299.

Nakhla AM, Khan MS, Romas NP & Rosner W (1994) Estradiol causes the rapid accumulation of cAMP in human prostate tissue.Proc Natl Acad Sci 91: 5402-5405.

Navratil H, Costa P, Louis JF, Andro MC & Saur P (1995) Efficacy and safety of intracavernous injection in patients with erectile dysfunction: dose/efect relationship versus placebo. Progres en Urologie 5: 690-696.

Nessel MA (1994) Yohimbine and pentoxyfylline in the treatment of erectile dysfunction . Am J Psychiatry 151: 453.

NIH Consensus Conference (1993) Impotence.NIH Consensus Development Panel on Impotence. JAMA 270: 83-90.

Nisen H & Cormio L (1993) Pharmacotesting with high dose prostaglandin E1 in impotence. Ann Chir et Gyn 82: 63-68.

Nisen HO, Saarinen O, Ruutu ML & Edgren J (1993) Duplex doppler scanning with prostaglandin E1 in the diagnosis of cavernous leakage. Acta Radiologica 34: 335-338.

O`Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA & Barry MJ (1995) A brief male sexual function inventory for urology. Urology 46: 697-706.

Ono N, Lumpkin MD, Samson WK, McDonald JK & McCann SM (1984) Intrahypothalamic action of corticotropin-releasing factor (CRF) to inhibit growth hormone and LH release in the rat. Life Sci 35: 1117-1123.

Osbon GD (1983) Erection aid device. US patent, 4, 378,008, Mar 29.

Padma-Nathan H & Goldstein I (1998) The pathogenesis of post-TURP impotence. J Urol 139: 275A.

Padma-Nathan H, Hellstrom WJG, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA & Gesundheit N (1997) Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336: 1-7.

Padma-Nathan H, Keller T & Proppiti R (1994) Hemodynamics effect of intraurethral alprostadil: the medicated urethral system for erection (MUSE). Int J Impot Res 6: A42.

Pearlman CK & Kobashi LI (1972) Frequency of intercouse in men. J Urol 107: 298-301.

Pescatori ES, Engelman JC, Davis G & Goldstein I (1993) Priapism of the clitoris: a case report following trazodone use. J Urol 149: 1557-1559.

Pescatori ES, Hatzichristou DG, Namburi S & Goldstein I (1994) A positive intracavernous injection test implies normal veno-occlusive but not necessarily normal arterial function: A hemodynamic study (see comments). J Urol 151: 1209-1216.

Piper PJ (1973) Distribution and metabolism. In Cuthbert MF (ed): Prostaglandins: Pharmacological and therapeutical advances. Philadelphia, Lippincott: 125-150.

Pont A, Williams PL, Azhar S, Reitz RE, Bochra C, Smith ER & Stevens DA (1982) Ketoconazole blocks testostreone synthesis. Arch Intern Med 142: 2137-2140.

Porst H (1990) Diagnostic use and side-efffects of vaso-active drugs: A report on over 2100 patients with erectile failure. Int J Impot Res 2(suppl 2): 222-223.

Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155: 802-815.

Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR & Osborn DE (1991) The management of impotence in diabetic men by vacuum tumescence therapy. Diabetic Med 8: 964-967.

Przybilla B & Schill WB (1985) Side-effects of drugs on male sexual function (Ger). Z Hautkreis 60: 1105-1114.

Quinlan DM, Epstein JI, Carter BS & Walsh PC (1991) Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 145: 998-1002.

Ravnik-Oblak M, Oblak C, Vodusek DB, Kristl V & Ziherl S (1990) Intracavernous injection of prostaglandin E1 In impotent diabetic men. Int J Impot Res 2: 143-150.

Reid K, Surridge DH, Morales A, Condra M, Harris C, Owen J & Fenemore J (1987) Double-blind trial of yohimbine in the treatment in the treatment of psychogenic impotence. Lancet II: 421-423.

Richter S, Gross R & Nissenkorn I (1990) Cavernous injection therapy for the treatment of erectile dysfunction in elderly men. Int J Impot Res 2: 43-47.

Rosen MP, Greenfield AJ, Walker TG, Grant P, Dubrow J, Bettman MA, Fried LE & Goldstein I (1991) Cigarette smoking: an indepedent risk factor for atherosclerosis in hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 145: 759-763.

Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J & Mishra A (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822-830.

Rowland DL, den Ouden AH & Slob AK (1994) The use of vibrotactile stimulation for determining sexual potency in the laboratory in men with erectile problems: methodological considerations. Int J Impot Res 6(3): 153-161.

Roy AC, Tan SM, Kottegoda SR & Ratnam SS (1984) Ability of human corpora cavernosa muscle to generate prostaglandins and thomboxanes in vitro IRCS Med Sci 12: 608-609.

Roy JB, Petrone RL & Said SI (1990) A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 143: 392-397.

Saenz de Tejada I, Ware JC, Blanco R, Pittard JT, Nadig PW, Azadzoi KM, Krane RJ & Goldstein I (1991) Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 145: 60-64.

Saenz de Tejada & Moncada I (1996) Pharmacology of penile smooth muscle. In book Porst H (Ed): Penile disorders. Proceedings of the International Symposium on Penile Disorders. p 125-143.

Sarosdy MF, Hudnall H, Erickson DR, Hardin TC & Novicki E (1989) A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence. J Urol 141: 551-553.

Sato Y, Suzuki N, Adachi H, Hisasue S, Horita H & Tsukamoto T (1998) Evaluation of alleviative action of neurotropin for penile pain associated with intracavernous injection of prostaglandin E1 assessed using the visual analogue scale. Int J Impot Res 10(1): 1-3.

Schramek P, Dorninger R, Waldhauser M, Konecny P & Porpaczy P (1990) Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Brit J Urol 65: 68-71.

Schramek P, Plas EG, Hubner WA & Pfluger (1994) Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction. J Urol 152: 1108-1110.

Schramek P & Waldhauser M (1989) Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction. Br J Clin Pharmacol 28: 567-571.

Seidmon EJ & Samaha AM JR (1989) The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacological erection. J Urol 146: 1458-1459.

Shabsigh R, Fishman IJ, Toombs BD & Skolkin M (1991) Venous leaks: anatomical and physiological observations. J Urol 146: 1260-1265.

Shabsigh R, Fishman IJ, Schum C & Dunn JK (1991) Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 38: 227-231.

Shirai T, Imaida K, Masui T, Iwasaki S, Mori T, Kato T & Ito N (1994) Effects of testosterone, dihydrotestosterone and estrogen on 3,2`dimethyl-4-aminobiphenyl-induced rat prostate carsinogenesis. Int J Cancer 57: 224-228.

Sister MP (1990) Prostaglandin E1 in erectile dysfunction: 20 months of experience with 483 patients in self-injection program. Int J Impot Res 2: 287-288.

Slag MF, Morley JE, Elson MK, Trence DL, Nelson CJ, Nelson AE, Kinlaw WB, Beyer HS, Nuttall FQ  Shafer RB (1983) Impotence in medical clinic outpatients. J.A.M.A. 249: 1736-1740.

Smith AD (1981) Causes and classification of impotence. Urol Clin N Amer 8: 79-89.

Sobotka JJ (1969) An evaluation of afrodex in the management of male impotency. Curr Ther Res 11: 87-97.

Sohn MH, Seeger U, Sikora R & Jakse G (1993) Criteria for examiner-independent nocturnal penile tumescence and rigidity monitoring (NPTR): Correlations to invasive diagnostic methods. Int J Impot Res 5: 59-68.

Sonda P, Mazo R & Chancellor MB (1990) The role of yohimbine for the treatment of erectile impotence. J Sex Marital Ther 16: 15-21.

Sorva R, Kuusi T, Taskinen M-R, Perheentupa J & Nikkilä EA (1988) Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 69: 191-197.

Spector IP & Carey MP(1990) Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Arch Sex Behav 19: 389-408.

Spratt DI, O`Dea LS, Schoenfeld D, Butler J, Rao PN & Crowley WF Jr (1988) Neuroendocrine-gonadal axis in men: Frequent sampling of LH, FSH and testosterone. Am J Physiol 254: E658-E666.

Stackl W Hasun R & Marberger M (1988) Intracavernous injection of prostaglandin E1 in impotent men. J Urol 140: 66-68.

Stackl W, Hasun R & Marberger M (1990) The use of prostaglandin E1 for diagnosis and treatment of erectile dysfunction. World J Urol 8: 84-86.

Stackl W, Stief CG, Benard F, Aboseif SR, Bosch RJ, Loupal G, Lue TF & Tanagho EA (1989) Intracavernous injection of solutions with different osmolarity and pH in the rabbit. Int J Impot Res 1: 197-200.

Stewart AL & Ware JE (eds) 1992 Measuring Function and Well-Being: The Medical Outcomes Study Approach. Durham and London: Duke University Press.

Stief CG, Benard F, Bosch JLHR, Aboseif SR, Lue TF & Tanagho EA (1990) A possible role for calcitonin-gene-related pepetide in the regulation of the smooth muscle tone of the bladder and penis. J Urol 143: 392-397.

Stief CG, Junemann KP, Kellner B, GerstenbergT, Merckx L & Wagner G (1994) Consensus and progress in corpus cavernosum-EMG (CC-EMG). Int J Impot Res 6: 177-182.

Surridge DHC, Lee JC, Morales A & Heaton PW (1998) Penile rigidity may supersede partner and counseling issues. J Urol 159: 5 supplement 114.

Susset JG, Tesier CD & Winze J (1989) Effect of yohimbine hydrochlorid on erectile impotence: a double-blind study. J Urol 141: 1360-1363.

Suzuki K, Takezawa Y, Suzuki T, Honma S & Yamaka H (1994) Synergistic effects of estrogen with androgen on the prostate-effects of estrogen on the prostate of androgen-adminstered rats and 5-alfa-reductase activity.Prostate 25: 169-176.

Swerdloff RS & Wang C (1993) Androgens and aging in men. Experimental Gerontology 28: 435-446.

Taylor S, Sutherland GR, Mackenzie GJ, Staunton HP & Donald HW (1965) The circulatory effect of intravenous phentolamine. Circulation 31: 741-754.

Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75: 1092-1098.

Theiss M, Hormockel G & Frohmuller HG (1995) Fournier`s gangrene in a patient with erectile dysfunction following use of mechanical erection aid device. J Urol 153: 1921-1922.

Turner LA, Althof SE, Levine SB, Tobias TR, Kursh ED, Bodner D & Resnick MI (1990) Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological an marital functioning. J Urol 144: 79-82.

Turner LA, Althof SE, Levine SB, Bodner DR, Kursh ED & Resnick MI (1991) External vacuum devices in the treatment of erectile dysfunction: a one-year study of sexual and psychosocial impact. J Sex Marital Ther 17: 81-93.

Turner LA, Althof SE, Levine SB, Bodner DR, Kursh ED & Resnick MI (1992) Twelve-month comparison of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 39: 139-144.

Wagner G (1981) Methods of differential diagnosis of psychogenic and organic erectile failure. In Wagner G, Green R (eds): Impotence. New York, Plenum, p 89-129.

Wagner G, Gerstenberg T (1988) Human in vivo studies of electrical activity of corpus cavernosum. J Urol 139: 327A.

Wagner G, Tejada IS (1998) Update on male erectile dysfunction. BMJ 316: 678-682.

Valdevenito R & Melman A (1994) Intracavernous self-injection pharmacotherapy program: Analysis of results and complications. Int J Impot Res 6: 81-91.

Walsh PC & Donker PJ (1982) Impotence following radical prostatectomy. J Urol 128: 492-497.

Wang Q & Large WA (1991) Modulation of noradrenaline-induced membrane currents by papaverine in rabbit vascular smooth muscle cells. J Physiol (Lond) 439: 501-512.

Wegner HEH, Knispel HH, Klän R, Meier T & Miller K (1994) Prostaglandin E1 versus Linsidomine Chlorhydrate in erectile dysfunction. Urol Int 53: 214-216.

Wein AJ, Fishkin R, Carpiniello VL & Malloy TR (1981) Expansion without significant rigidity during nocturnal penile tumescence testing: A potential source of misinterpretation. J Urol 126: 343-344.

Wein AJ & Van Arsdalen KN (1988) Drug-induced male sexual dysfunction. Urol Clin N Amer 15: 23.

Weiske EH (1996) Epidemiology and diagnostics of erectile dysfunction. In book Porst H (ed): penile disorders; proceedings of the international symposium on penile disorders. Hamburg, Germany, January 26-27. Springler, p 120-121.

Vermeulen A (1993) The male climacterium: Ann Med 25: 531-534.

Wespes E, Delcour C, Struyven J & Schulman CC (1986) Pharmacocavernometry-cavernography in impotence. Br J Urol 58: 429-433.

Wespes E, Moreira de Goes P & Schulman C (1992) vascular impotence:focal or diffuse penile disease. J Urol 148: 1435-1436.

Virag R & Adaikan PG (1987) Effects of prostaglandin E1 on penile erection and and erectile failure. J Urol 137: 1010 (letter).

Virag R, Frydman D, Legman M & Virag H (1984) Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 35: 79-87.

Virag R, Shoukry K, Floresco J, Nollet F & Greco E (1991) Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 145: 287-293.

Virag R (1982) Intracavernous injection of papaverine for erectile failure (letter). Lancet II: 938.

Witherington R (1989) Vacuum constriction device for management of erectile dysfunction. J Urol 141: 320-322.

Witjes WP, Meuleman EJ, Lycklama N, Van Driel MF, Leliefeld HH, Kropman RF & Doesburg WH (1992) the efficiacy and acceptance of intracavernous autoinjection therapy with the combination of papaverine/ phentolamine. A prospective multicenter trial. Int J Impot Res 4: 65-71.

Von Graffenreid B, del Pozo E, Roubiceck J, Roubicek J, Krebs E, Pöldinger W, Burmeister P & Kerp L (1978) Effects of synthetic enkephalin analogue FK 33-824 in man. Nature 272: 729-730.

Von Heyden B, Donatucci CF, Marshall GA, Brock GB & Lue TF (1993) A prostaglandin E1 dose-response study in man. J Urol 150: 1825-1828.

Vrijhof HJ & Delaere KP (1994) Vacuum constriction devices in erectile dysfunction vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol 74: 102-105.

Vruggink PA, Diemont WL, Debruyne FM & Meuleman EJ (1995) Enhanced pharmacological testing in patients with erectile dysfunction. J Androl 16(2): 163-168

Yalcin S, Altundag K, Asil M & Tekuzman G (1998) Sublingual piroxicam for cancer pain. Med Oncol 15 (2): 137-139.

Zeiss AM, Davies HD, Wood M & Tinklenberg JR (1990) The incidence and correlates of erectile problems in patients with Alzheimer`s disease. Arch Sex Behav 19: 325-331.

Zorgniotti AW (1992) ´On demand´oral drug for erection in impotent men. J Urol 147: 308A.

Zorgniotti AW & Lefleur RS (1985) Auto-injection of corpus cavernosum with vasoactive drug combination of vasculogenic impotence. J Urol 133: 39-41.

Zorgniotti AW & Lizza AF (1994) Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 6: 33-35.